Navigation Links
AMDL Signs MOU for 200 Store Distribution Arrangements for Goodnak Product Line
Date:4/30/2008

TUSTIN, Calif., April 30 /PRNewswire-FirstCall/ -- AMDL, Inc. (Amex: ADL), headquartered in Tustin, California, with operations in Shenzhen, Jiangxi, and Jilin, China, is a vertically integrated specialty pharmaceutical company. In combination with its subsidiary Jade Pharmaceutical Inc., (JPI), the Company engages in the research, development, manufacturing, and marketing of diagnostic, pharmaceutical, nutritional supplement, and cosmetic products.

AMDL today announced that JPI has signed a Memorandum of Understanding (MOU) with Zhejiang HuaDu Beauty Co. Ltd. HuaDu owns more than 200 beauty stores and a beauty care training school located in Zhejiang province. The MOU creates a path for HuaDu to sell JPI's Goodnak anti-aging product and a new to-be-launched set of seven new Goodnak non-injectable anti-aging human products. These seven new Goodnak products are anticipated to be marketed during the second and third quarters of 2008.

JPI also recently held a conference in the city of Hangzhou to discuss with various beauty salon operators and regional hospitals the development of JPGREEN Anti-Aging Clinics. These clinics would be developed primarily through the conversion of existing operations into JPGREEN Anti-Aging Clinics locations. It is anticipated that a minimum of 100 JPGREEN Anti-Aging Clinics and at least 13 Hospital operated therapeutic anti-aging clinics would be developed over the next 12 months.

Mr. Gary Dreher, CEO of AMDL, noted that "our new JPGREEN Anti-Aging Clinics concept appears to be the most prudent path to developing and expanding this important area of JPI's business."

About Jade Pharmaceutical: JPI has access to the fastest growing pharmaceutical and consumer market in the world: China. AMDL, through its subsidiaries, JPI currently manufactures large volume injection fluids, tablets and other related products, holding licenses for 133 products. It also manufactures 107 generic, over the counter and supplemental pharmaceutical products under certified Chinese Good Manufacturing Practice (CGMP) standards.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.

About AMDL: More information about AMDL and its products can be obtained at http://www.amdl.com.

Contact: AMDL, Inc.

Mr. Paul Knopick

AMDL Investor Relations

Direct Line: 949.707.5365

Voice Mail: 714.505.4460


'/>"/>
SOURCE AMDL, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Nihon LocalSoft Designs New Japanese Software for IRadimed Corporations Award-Winning MRidium MRI Infusion System
2. President Signs Elder Falls Bill Into Law
3. Phyhealth Signs Agreement with Advantica EyeCare to Provide Vision Services for Pilot HMO
4. Xceed Molecular Signs University of Florida to Strategic Collaborator Program; Focus on Developing New Molecular Test to Diagnose Early-Stage Bladder Cancer
5. Breckenridge Pharmaceutical Signs Letter of Intent for Long Term Agreement With Orit Laboratories (West Caldwell, NJ)
6. New Patient Monitoring Devices Handle More Than Just Vital Signs
7. Medical Futures signs North American licensing rights to New Biologic agent for Ulcerative Colitis
8. Governor Rendell Signs Bill Into Law
9. Medical Marketing Veteran Signs on as Director of Strategy and New Business Development at Active Imagination
10. Pharsight Signs New Diabetes Meta-Database Customer
11. Governor Strickland Signs House Bill 125 Into Law
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... March 24, 2017 , ... Vighter established its NAEMT Authorized ... providing Prehospital Trauma Life Support (PHTLS) course scholarships to four medics assigned to ... developed in cooperation with the American College of Surgeons to promote critical thinking ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... world countries to hospitals in the United States, it’s a threat that is ... current obstacles facing infection prevention and offers strategies for the healthcare community to ...
(Date:3/24/2017)... Farifax, VA (PRWEB) , ... March 24, 2017 , ... ... its 2017 Quest Awards . The annual awards, now in their 12th year, ... marketing peers selects the winners. , In 2016, the awards were retooled to recognize ...
(Date:3/24/2017)... ... , ... Texas Physical Therapy Specialists (TexPTS) is pleased to announce the ... clinic is the group’s 7th location in San Antonio and 23rd in Texas. ... care from the clinic, which opened March 22, 2017. , The team ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... related services to families and business owners across eastern Michigan, is connecting with ... families struggling with financial difficulties. , The Oxford/Orion FISH Food Pantry works to ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... LONDON , March 23, 2017 ... comprehensive research report created through extensive primary research ... research, the report aims to present the analysis ... basis of Procedure (Replacement and Repair); Replacement Procedure ... (TAVR)), Repair By Technique (Surgical Devices, Balloon Valvuloplasty, ...
(Date:3/23/2017)... 23, 2017  The U.S. Food and Drug Administration ... treatment of adults and pediatric patients 12 years and ... who have not received prior chemotherapy. This is the ... form of skin cancer. "While skin cancer ... a rare form called Merkel cell cancer have not ...
(Date:3/23/2017)... SAN DIEGO and VANCOUVER, British ... Inc. (NASDAQ: SPHS ) (the "Company" or ... for the treatment of urological diseases, today announced that ... which evaluated the drug as a focal treatment for ... on March 26, 2017 at the 32 nd ...
Breaking Medicine Technology: